Interleukin-6-174 Promoter Polymorphism and Susceptibility to Hepatitis B Virus Infection as a Risk Factor for Hepatocellular Carcinoma in Iran

  • Attar, Marzieh (Medical Cellular and Molecular Research Center, Golestan University of Medical Sciences) ;
  • Azar, Saleh Shahbazi (Medical Cellular and Molecular Research Center, Golestan University of Medical Sciences) ;
  • Shahbazi, Majid (Medical Cellular and Molecular Research Center, Golestan University of Medical Sciences)
  • Published : 2016.05.01


Background: Hepatitis B virus (HBV) is a major risk factor for hepatocellular carcinoma (HCC). Cytokines play an important role in the regulation of immune responses and defense against viral infections. Human interleukin 6 (IL6) is a multifunctional cytokine that participates in these processes. Objective: The aim of this study was to assess the IL6-174 gene polymorphism in patients with chronic hepatitis B virus (HBV) infection as compared with healthy controls in an Iranian population. Materials and Methods: Totals of 297 HBV patients and 368 control individuals were evaluated. Genomic DNA was extracted from peripheral blood and the SSP-PCR (sequence specific primer-polymerase chain reaction) method was applied for genotyping. Results: The frequencies of genotypes C/C, G/G and C/G in HBV cases were 4.7%, 34.3%, 60.9% and in controls were 12.8%, 39.7% and 47.6%, respectively. The frequencies of G and C allele in patients and controls were 78.1%, 21.9% and 67.4%, 32.6 % respectively. There was a significant difference in the frequencies of G/G genotype (CI=1.8-7.1, OR=3.47, P=0.00001) and G allele (CI=1.34-2.23, OR=1.72, P=0.0001) between HBV patients and the control group. Conclusions: These findings suggest that the IL6-174 C/G genotype and the G allele are strongly associated with susceptibility to HBV infection. Demographic information showed that most of the subjects were male (74.4%). According to high frequency of G/G genotype in male participants (63.1%) men probably are more susceptible to hepatitis than women.


Hepatitis B virus (HBV);hepatocellular carcinoma (HCC);interleukin-6;Iran;polymerase chain reaction


Supported by : Golestan University of Medical Sciences


  1. Ben-Ari Z, Mor E, Papo O, et al (2003). Cytokine gene polymorphisms in patients infected with hepatitis B virus. Am J Gastroenterol, 98, 144-50.
  2. Capurso C, Solfrizzi V, D'Introno A, et al (2004). Interleukin 6-174 G/C promoter gene polymorphism and sporadic Alzheimer's disease: geographic allele and genotype variations in Europe. Exp Gerontol, 39, 1567-73.
  3. Chanthra N, Payungporn S, Chuaypen N, et al (2015). Single Nucleotide Polymorphisms in STAT3 and STAT4 and Risk of Hepatocellular Carcinoma in Thai Patients with Chronic Hepatitis B. Asian Pac J Cancer Prev, 16, 8405-10.
  4. Colombo M, Kuo G, Choo QL, et al (1989). Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet, 2, 1006-8.
  5. Cussigh A, Falleti E, Fabris C, et al (2011). Interleukin 6 promoter polymorphisms influence the outcome of chronic hepatitis C. Immunogenetics, 63, 33-41.
  6. Fabris C, Toniutto P, Bitetto D, et al (2009). Gene polymorphism at the interleukin 6 -174 G > C locus affects the outcome of chronic hepatitis B. J Infect, 59, 144-5.
  7. Fallot G, Neuveut C, Buendia MA (2012). Diverse roles of hepatitis B virus in liver cancer. Curr Opin Virol, 2, 467-73.
  8. Fernandez-Real JM, Broch M, Vendrell J, et al (2000). Interleukin-6 gene polymorphism and insulin sensitivity. Diabetes, 49, 517-20.
  9. Fishman D, Faulds G, Jeffery R, et al (1998). The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest, 102, 1369-76.
  10. Galun E, Nahor O, Eid A, et al (2000). Human interleukin-6 facilitates hepatitis B virus infection in vitro and in vivo. Virol, 270, 299-309.
  11. Gao J, Xie L, Yang WS, et al (2012). Risk factors of hepatocellular carcinoma--current status and perspectives. Asian Pac J Cancer Prev, 13, 743-52.
  12. Hajiani E, Masjedizadeh R, Hashemi J, et al (2005). Risk factors for hepatocellular carcinoma in Southern Iran. Saudi Med J, 26, 974-7.
  13. Hamid YH, Rose CS, Urhammer SA, et al (2005). Variations of the interleukin-6 promoter are associated with features of the metabolic syndrome in Caucasian Danes. Diabetologia, 48, 251-60.
  14. Jeng JE, Wu HF, Tsai MF, et al (2014). Independent and additive interaction between tumor necrosis factor beta +252 polymorphisms and chronic hepatitis B and C virus infection on risk and prognosis of hepatocellular carcinoma: a case-control study. Asian Pac J Cancer Prev, 15, 10209-15.
  15. Kakumu S, Shinagawa T, Ishikawa T, et al (1993). Interleukin 6 production by peripheral blood mononuclear cells in patients with chronic hepatitis B virus infection and primary biliary cirrhosis. Gastroenterol Jpn, 28, 18-24.
  16. Kim YJ, Lee HS, Yoon JH, et al (2003). Association of TNF-alpha promoter polymorphisms with the clearance of hepatitis B virus infection. Hum Mol Genet, 12, 2541-6.
  17. Kumar V, Abbas AK, Fausto N, et al (2014). Robbins and cotran pathologic basis of disease, elsevier health sciences.
  18. Kummee P, Tangkijvanich P, Poovorawan Y, et al (2007). Association of HLA-DRB1*13 and TNF-alpha gene polymorphisms with clearance of chronic hepatitis B infection and risk of hepatocellular carcinoma in Thai population. J Viral Hepat, 14, 841-8.
  19. Li N, Gao YF, Zhang TC, et al (2012). Relationship between interleukin 18 polymorphisms and susceptibility to chronic hepatitis B virus infection. World J Hepatol, 4, 105-9.
  20. Limothai U, Wasitthankasem R, Poovorawan Y, et al (2015). Single nucleotide polymorphism of interferon lambda-4 gene is not associated with treatment response to pegylated interferon in thai patients with chronic hepatitis B. Asian Pac J Cancer Prev, 16, 5515-9.
  21. Lu Y, Bao JG, Deng Y, et al (2015). Role of IL-18 gene promoter polymorphisms, serum il-18 levels, and risk of hepatitis b virus-related liver disease in the guangxi zhuang population: a retrospective case-control study. Asian Pac J Cancer Prev, 16, 6019-26.
  22. Malaguarnera M, Di Fazio I, Laurino A, et al (1997). Serum interleukin 6 concentrations in chronic hepatitis C patients before and after interferon-alpha treatment. Int J Clin Pharmacol Ther, 35, 385-8.
  23. Mansoori M, Golalipour M, Alizadeh S, et al (2015). Genetic variation in the ABCB1 gene may lead to mRNA level chabge: application to gastric cancer cases. asian pac j cancer prev, 16, 8467-71.
  24. Merat S, Malekzadeh R, Rezvan H, et al (2000). Hepatitis B in Iran. Arch Iran Med, 3, 192-201.
  25. Migita K, Miyazoe S, Maeda Y, et al (2005). Cytokine gene polymorphisms in Japanese patients with hepatitis B virus infection-association between TGF-${\beta}1$ polymorphisms and hepatocellular carcinoma. J Hepatol, 42, 505-10.
  26. Nattermann J, Vogel M, Berg T, et al (2007). Effect of the interleukin-6 C174G gene polymorphism on treatment of acute and chronic hepatitis C in human immunodeficiency virus coinfected patients. Hepatol, 46, 1016-25.
  27. Nun-Anan P, Chonprasertsuk S, Siramolpiwat S, et al (2015). CYP2C19 genotype could be a predictive factor for aggressive manifestations of hepatocellular carcinoma related with chronic hepatitis B infection in Thailand. Asian Pac J Cancer Prev, 16, 3253-6.
  28. Park BL, Lee HS, Kim YJ, et al (2003). Association between interleukin 6 promoter variants and chronic hepatitis B progression. Exp Mol Med, 35, 76-82.
  29. Parkin DM, Bray F, Ferlay J, et al (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108.
  30. Pourhoseingholi MA, Fazeli Z, Zali MR, et al (2010). Burden of hepatocellular carcinoma in Iran; Bayesian projection and trend analysis. Asian Pac J Cancer Prev, 11, 859-62.
  31. Rapicetta M, Ferrari C, Levrero M (2002). Viral determinants and host immune responses in the pathogenesis of HBV infection. J Med Virol, 67, 454-7.
  32. Shahbazi M, Ebadi H, Fathi D, et al (2010). HLA-DRB1*1501 intensifies the impact of IL-6 promoter polymorphism on the susceptibility to multiple sclerosis in an Iranian population. Mult Scler, 16, 1173-7.
  33. Shahbazi M, Pravica V, Nasreen N, et al (2002). Association between functional polymorphism in EGF gene and malignant melanoma. Lancet, 359, 397-401.
  34. Shamszad M, Farzadegan H (1982). Hepatitis B related cirrhosis and hepatocellular carcinoma in Iran. J Irn Med Council, 8, 238.
  35. Song W, Zhang F, Li Z (2000). [A quantitative analysis of IL-6 mRNA expression of peripheral blood monocyte cell in patients with chronic hepatitis B]. Zhonghua Gan Zang Bing Za Zhi, 8, 346-7.
  36. Tayebi S, Mohamadkhani A (2012). The TNF-alpha -308 promoter gene polymorphism and chronic HBV infection. Hepat Res Treat, 2012, 493219.
  37. Terry CF, Loukaci V, Green FR (2000). Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem, 275, 18138-44.
  38. Wang C, Tang J, Song W, et al (2004). HLA and cytokine gene polymorphisms are independently associated with responses to hepatitis B vaccination. Hepatol, 39, 978-88.
  39. Wang CH, Wey KC, Mo LR, et al (2015). Current trends and recent advances in diagnosis, therapy, and prevention of hepatocellular carcinoma. Asian Pac J Cancer Prev, 16, 3595-604.